Press Releases<< Back
CHF Solutions Announces the Launch of Pediatric Ultrafiltration Therapy Using the Aquadex SmartFlow System at Children’s Hospital of The King’s Daughters
“Following FDA clearance and the launch of the Aquadex SmartFlow system in the first quarter, we continue to see strong interest from pediatric hospitals,” said
“We will use this ultrafiltration therapy to accommodate the needs of children that require fluid removal without the added risk of hemodialysis and to meet the needs of ICU patients with heart disease that don’t respond to diuretics,” said Dr.
About Children’s Hospital of The King’s Daughters
CHKD is the only freestanding children’s hospital in
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the increased interest in therapy using the Aquadex SmartFlow system with pediatric patients. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our expectations regarding the potential impacts of the COVID-19 pandemic on our business operations, our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
Claudia Napal DraytonChief Financial Officer, CHF Solutions, Inc.952-345-4205 firstname.lastname@example.org MEDIA: Jessica StebingHealth+Commerce 260-336-6202 email@example.com
Source: CHF Solutions, Inc.